nodes	percent_of_prediction	percent_of_DWPC	metapath
Metaxalone—Irritability—Valrubicin—urinary bladder cancer	0.0572	0.0572	CcSEcCtD
Metaxalone—Drowsiness—Mitomycin—urinary bladder cancer	0.0318	0.0318	CcSEcCtD
Metaxalone—Leukopenia—Mitomycin—urinary bladder cancer	0.0223	0.0223	CcSEcCtD
Metaxalone—Pruritus—Valrubicin—urinary bladder cancer	0.0208	0.0208	CcSEcCtD
Metaxalone—Dizziness—Valrubicin—urinary bladder cancer	0.0195	0.0195	CcSEcCtD
Metaxalone—Vomiting—Valrubicin—urinary bladder cancer	0.0187	0.0187	CcSEcCtD
Metaxalone—Rash—Valrubicin—urinary bladder cancer	0.0186	0.0186	CcSEcCtD
Metaxalone—Dermatitis—Valrubicin—urinary bladder cancer	0.0186	0.0186	CcSEcCtD
Metaxalone—Headache—Valrubicin—urinary bladder cancer	0.0184	0.0184	CcSEcCtD
Metaxalone—Anaphylactoid reaction—Gemcitabine—urinary bladder cancer	0.018	0.018	CcSEcCtD
Metaxalone—Somnolence—Mitomycin—urinary bladder cancer	0.018	0.018	CcSEcCtD
Metaxalone—Haemolytic anaemia—Cisplatin—urinary bladder cancer	0.018	0.018	CcSEcCtD
Metaxalone—Nausea—Valrubicin—urinary bladder cancer	0.0175	0.0175	CcSEcCtD
Metaxalone—Anaphylactoid reaction—Cisplatin—urinary bladder cancer	0.0168	0.0168	CcSEcCtD
Metaxalone—Irritability—Fluorouracil—urinary bladder cancer	0.0164	0.0164	CcSEcCtD
Metaxalone—Jaundice—Thiotepa—urinary bladder cancer	0.0156	0.0156	CcSEcCtD
Metaxalone—Irritability—Cisplatin—urinary bladder cancer	0.0155	0.0155	CcSEcCtD
Metaxalone—Anaphylactoid reaction—Etoposide—urinary bladder cancer	0.0154	0.0154	CcSEcCtD
Metaxalone—Abdominal discomfort—Cisplatin—urinary bladder cancer	0.0135	0.0135	CcSEcCtD
Metaxalone—Dizziness—Mitomycin—urinary bladder cancer	0.0134	0.0134	CcSEcCtD
Metaxalone—Vomiting—Mitomycin—urinary bladder cancer	0.0129	0.0129	CcSEcCtD
Metaxalone—Rash—Mitomycin—urinary bladder cancer	0.0128	0.0128	CcSEcCtD
Metaxalone—Dermatitis—Mitomycin—urinary bladder cancer	0.0128	0.0128	CcSEcCtD
Metaxalone—Headache—Mitomycin—urinary bladder cancer	0.0127	0.0127	CcSEcCtD
Metaxalone—Tension—Thiotepa—urinary bladder cancer	0.0123	0.0123	CcSEcCtD
Metaxalone—Nervousness—Thiotepa—urinary bladder cancer	0.0121	0.0121	CcSEcCtD
Metaxalone—Nausea—Mitomycin—urinary bladder cancer	0.0121	0.0121	CcSEcCtD
Metaxalone—Jaundice—Etoposide—urinary bladder cancer	0.0112	0.0112	CcSEcCtD
Metaxalone—Leukopenia—Thiotepa—urinary bladder cancer	0.0112	0.0112	CcSEcCtD
Metaxalone—Leukopenia—Gemcitabine—urinary bladder cancer	0.00941	0.00941	CcSEcCtD
Metaxalone—Leukopenia—Fluorouracil—urinary bladder cancer	0.00926	0.00926	CcSEcCtD
Metaxalone—Anaphylactoid reaction—Methotrexate—urinary bladder cancer	0.00923	0.00923	CcSEcCtD
Metaxalone—Somnolence—Thiotepa—urinary bladder cancer	0.00907	0.00907	CcSEcCtD
Metaxalone—Leukopenia—Cisplatin—urinary bladder cancer	0.00877	0.00877	CcSEcCtD
Metaxalone—Anaphylactoid reaction—Epirubicin—urinary bladder cancer	0.00864	0.00864	CcSEcCtD
Metaxalone—Anaphylactic shock—Gemcitabine—urinary bladder cancer	0.00858	0.00858	CcSEcCtD
Metaxalone—Irritability—Methotrexate—urinary bladder cancer	0.00853	0.00853	CcSEcCtD
Metaxalone—Anaphylactic shock—Fluorouracil—urinary bladder cancer	0.00844	0.00844	CcSEcCtD
Metaxalone—Leukopenia—Etoposide—urinary bladder cancer	0.00804	0.00804	CcSEcCtD
Metaxalone—Anaphylactic shock—Cisplatin—urinary bladder cancer	0.008	0.008	CcSEcCtD
Metaxalone—Anaphylactoid reaction—Doxorubicin—urinary bladder cancer	0.00799	0.00799	CcSEcCtD
Metaxalone—Somnolence—Gemcitabine—urinary bladder cancer	0.00763	0.00763	CcSEcCtD
Metaxalone—Hypersensitivity—Thiotepa—urinary bladder cancer	0.00752	0.00752	CcSEcCtD
Metaxalone—Somnolence—Fluorouracil—urinary bladder cancer	0.0075	0.0075	CcSEcCtD
Metaxalone—Abdominal discomfort—Methotrexate—urinary bladder cancer	0.0074	0.0074	CcSEcCtD
Metaxalone—Anaphylactic shock—Etoposide—urinary bladder cancer	0.00733	0.00733	CcSEcCtD
Metaxalone—Pruritus—Thiotepa—urinary bladder cancer	0.00722	0.00722	CcSEcCtD
Metaxalone—Drowsiness—Methotrexate—urinary bladder cancer	0.00688	0.00688	CcSEcCtD
Metaxalone—Dizziness—Thiotepa—urinary bladder cancer	0.00675	0.00675	CcSEcCtD
Metaxalone—Somnolence—Etoposide—urinary bladder cancer	0.00652	0.00652	CcSEcCtD
Metaxalone—Vomiting—Thiotepa—urinary bladder cancer	0.00649	0.00649	CcSEcCtD
Metaxalone—Drowsiness—Epirubicin—urinary bladder cancer	0.00644	0.00644	CcSEcCtD
Metaxalone—Rash—Thiotepa—urinary bladder cancer	0.00643	0.00643	CcSEcCtD
Metaxalone—Dermatitis—Thiotepa—urinary bladder cancer	0.00643	0.00643	CcSEcCtD
Metaxalone—Headache—Thiotepa—urinary bladder cancer	0.00639	0.00639	CcSEcCtD
Metaxalone—Jaundice—Epirubicin—urinary bladder cancer	0.00628	0.00628	CcSEcCtD
Metaxalone—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.00622	0.00622	CcSEcCtD
Metaxalone—Pruritus—Gemcitabine—urinary bladder cancer	0.00607	0.00607	CcSEcCtD
Metaxalone—Nausea—Thiotepa—urinary bladder cancer	0.00606	0.00606	CcSEcCtD
Metaxalone—Pruritus—Fluorouracil—urinary bladder cancer	0.00597	0.00597	CcSEcCtD
Metaxalone—Drowsiness—Doxorubicin—urinary bladder cancer	0.00596	0.00596	CcSEcCtD
Metaxalone—Hypersensitivity—Cisplatin—urinary bladder cancer	0.00589	0.00589	CcSEcCtD
Metaxalone—Jaundice—Doxorubicin—urinary bladder cancer	0.00581	0.00581	CcSEcCtD
Metaxalone—Dizziness—Fluorouracil—urinary bladder cancer	0.00558	0.00558	CcSEcCtD
Metaxalone—Vomiting—Gemcitabine—urinary bladder cancer	0.00546	0.00546	CcSEcCtD
Metaxalone—Rash—Gemcitabine—urinary bladder cancer	0.00541	0.00541	CcSEcCtD
Metaxalone—Dermatitis—Gemcitabine—urinary bladder cancer	0.00541	0.00541	CcSEcCtD
Metaxalone—Hypersensitivity—Etoposide—urinary bladder cancer	0.0054	0.0054	CcSEcCtD
Metaxalone—Headache—Gemcitabine—urinary bladder cancer	0.00538	0.00538	CcSEcCtD
Metaxalone—Vomiting—Fluorouracil—urinary bladder cancer	0.00537	0.00537	CcSEcCtD
Metaxalone—Rash—Fluorouracil—urinary bladder cancer	0.00532	0.00532	CcSEcCtD
Metaxalone—Dermatitis—Fluorouracil—urinary bladder cancer	0.00532	0.00532	CcSEcCtD
Metaxalone—Headache—Fluorouracil—urinary bladder cancer	0.00529	0.00529	CcSEcCtD
Metaxalone—Pruritus—Etoposide—urinary bladder cancer	0.00519	0.00519	CcSEcCtD
Metaxalone—Nausea—Gemcitabine—urinary bladder cancer	0.0051	0.0051	CcSEcCtD
Metaxalone—Vomiting—Cisplatin—urinary bladder cancer	0.00509	0.00509	CcSEcCtD
Metaxalone—Rash—Cisplatin—urinary bladder cancer	0.00504	0.00504	CcSEcCtD
Metaxalone—Dermatitis—Cisplatin—urinary bladder cancer	0.00504	0.00504	CcSEcCtD
Metaxalone—Nausea—Fluorouracil—urinary bladder cancer	0.00501	0.00501	CcSEcCtD
Metaxalone—Tension—Epirubicin—urinary bladder cancer	0.00494	0.00494	CcSEcCtD
Metaxalone—Nervousness—Epirubicin—urinary bladder cancer	0.00489	0.00489	CcSEcCtD
Metaxalone—Dizziness—Etoposide—urinary bladder cancer	0.00485	0.00485	CcSEcCtD
Metaxalone—Leukopenia—Methotrexate—urinary bladder cancer	0.00481	0.00481	CcSEcCtD
Metaxalone—Nausea—Cisplatin—urinary bladder cancer	0.00475	0.00475	CcSEcCtD
Metaxalone—Vomiting—Etoposide—urinary bladder cancer	0.00466	0.00466	CcSEcCtD
Metaxalone—Rash—Etoposide—urinary bladder cancer	0.00462	0.00462	CcSEcCtD
Metaxalone—Dermatitis—Etoposide—urinary bladder cancer	0.00462	0.00462	CcSEcCtD
Metaxalone—Headache—Etoposide—urinary bladder cancer	0.00459	0.00459	CcSEcCtD
Metaxalone—Tension—Doxorubicin—urinary bladder cancer	0.00457	0.00457	CcSEcCtD
Metaxalone—Nervousness—Doxorubicin—urinary bladder cancer	0.00452	0.00452	CcSEcCtD
Metaxalone—Leukopenia—Epirubicin—urinary bladder cancer	0.00451	0.00451	CcSEcCtD
Metaxalone—Anaphylactic shock—Methotrexate—urinary bladder cancer	0.00439	0.00439	CcSEcCtD
Metaxalone—Nausea—Etoposide—urinary bladder cancer	0.00435	0.00435	CcSEcCtD
Metaxalone—Leukopenia—Doxorubicin—urinary bladder cancer	0.00417	0.00417	CcSEcCtD
Metaxalone—Anaphylactic shock—Epirubicin—urinary bladder cancer	0.00411	0.00411	CcSEcCtD
Metaxalone—Somnolence—Methotrexate—urinary bladder cancer	0.0039	0.0039	CcSEcCtD
Metaxalone—Anaphylactic shock—Doxorubicin—urinary bladder cancer	0.0038	0.0038	CcSEcCtD
Metaxalone—Somnolence—Epirubicin—urinary bladder cancer	0.00365	0.00365	CcSEcCtD
Metaxalone—Somnolence—Doxorubicin—urinary bladder cancer	0.00338	0.00338	CcSEcCtD
Metaxalone—Hypersensitivity—Methotrexate—urinary bladder cancer	0.00323	0.00323	CcSEcCtD
Metaxalone—Pruritus—Methotrexate—urinary bladder cancer	0.00311	0.00311	CcSEcCtD
Metaxalone—Hypersensitivity—Epirubicin—urinary bladder cancer	0.00303	0.00303	CcSEcCtD
Metaxalone—Pruritus—Epirubicin—urinary bladder cancer	0.00291	0.00291	CcSEcCtD
Metaxalone—Dizziness—Methotrexate—urinary bladder cancer	0.0029	0.0029	CcSEcCtD
Metaxalone—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.0028	0.0028	CcSEcCtD
Metaxalone—Vomiting—Methotrexate—urinary bladder cancer	0.00279	0.00279	CcSEcCtD
Metaxalone—Rash—Methotrexate—urinary bladder cancer	0.00277	0.00277	CcSEcCtD
Metaxalone—Dermatitis—Methotrexate—urinary bladder cancer	0.00277	0.00277	CcSEcCtD
Metaxalone—Headache—Methotrexate—urinary bladder cancer	0.00275	0.00275	CcSEcCtD
Metaxalone—Dizziness—Epirubicin—urinary bladder cancer	0.00272	0.00272	CcSEcCtD
Metaxalone—Pruritus—Doxorubicin—urinary bladder cancer	0.00269	0.00269	CcSEcCtD
Metaxalone—Vomiting—Epirubicin—urinary bladder cancer	0.00261	0.00261	CcSEcCtD
Metaxalone—Nausea—Methotrexate—urinary bladder cancer	0.00261	0.00261	CcSEcCtD
Metaxalone—Rash—Epirubicin—urinary bladder cancer	0.00259	0.00259	CcSEcCtD
Metaxalone—Dermatitis—Epirubicin—urinary bladder cancer	0.00259	0.00259	CcSEcCtD
Metaxalone—Headache—Epirubicin—urinary bladder cancer	0.00257	0.00257	CcSEcCtD
Metaxalone—Dizziness—Doxorubicin—urinary bladder cancer	0.00251	0.00251	CcSEcCtD
Metaxalone—Nausea—Epirubicin—urinary bladder cancer	0.00244	0.00244	CcSEcCtD
Metaxalone—Vomiting—Doxorubicin—urinary bladder cancer	0.00242	0.00242	CcSEcCtD
Metaxalone—Rash—Doxorubicin—urinary bladder cancer	0.0024	0.0024	CcSEcCtD
Metaxalone—Dermatitis—Doxorubicin—urinary bladder cancer	0.00239	0.00239	CcSEcCtD
Metaxalone—Headache—Doxorubicin—urinary bladder cancer	0.00238	0.00238	CcSEcCtD
Metaxalone—Nausea—Doxorubicin—urinary bladder cancer	0.00226	0.00226	CcSEcCtD
